SIMCERE PHARMA (02096) spent 10.1667 million Hong Kong dollars to repurchase 1.49 million shares on November 18th.
Sinopharm (02096) announced that on November 18, 2024, the company invested 1016.67 million...
SIMCERE PHARMA (02096) announced that on November 18, 2024, the company repurchased 1.49 million shares at a cost of 10.167 million Hong Kong dollars. The repurchase price was between 6.71 and 6.98 Hong Kong dollars per share.
Related Articles
Jiangsu Hengrui Pharmaceuticals (01276): The third indication for injectable rexinoid trastuzumab has been approved for market launch.
Selected announcements from A-shares | Yushu Technology (688836.SH): Initial public offering price of 150.8 yuan per share.
CANOPY SKYFIRE (08245): Ye Shanlan resigns as an independent non-executive director.
Jiangsu Hengrui Pharmaceuticals (01276): The third indication for injectable rexinoid trastuzumab has been approved for market launch.
Selected announcements from A-shares | Yushu Technology (688836.SH): Initial public offering price of 150.8 yuan per share.
CANOPY SKYFIRE (08245): Ye Shanlan resigns as an independent non-executive director.
RECOMMEND
